LAS VEGAS, Nov. 3, 2006 (PRIMEZONE) -- Samaritan Pharmaceuticals Inc. (AMEX:LIV) a developer of innovative drugs, announced today we have received notice of the publication of its novel anti-amyloidal Alzheimer's drug Caprospinol (SP-233) by the World Intellectual Property Organization ("WIPO"). The WIPO Patent Application Number is WO2006107902 and is entitled: USE OF SPIROSTENOLS TO TREAT MITOCHONDRIAL DISORDERS.
http://v3.espacenet.com/textdoc?DB=EPODOC&IDX=WO2006107902&F=0&QPN=WO2006107902
The publication covers several unique features of Caprospinol's (SP-233) anti-amyloid properties; i.e. protecting neuronal cells against neurotoxicity by protecting mitochondria functions against the toxic effects of beta-amyloid.
Eugene Boyle, CFO of Samaritan, and Patent Agent, stated, "We are extremely pleased with our patent portfolio and this publication allows everyone a first look and early access to examining Samaritan's exciting technology. I look forward to facilitating its growth, as issued patents can be the bedrock of increased valuations."
The publication of the patent application means the WIPO has disclosed the invention for public review and comment of claims contained in the patent. The patent has not been "approved" or "issued," therefore it still an application.
Samaritan Pharmaceuticals: "We LIV... to Save Lives."
Samaritan is a small-cap Biotech, driven to discover, develop and commercialize innovative therapeutics for AIDS, Alzheimer's, Cancer and Heart disease patients. Look at www.samaritanpharma.com. Please register on Website so we can notify you of upcoming conference calls, news and events.
The Samaritan Pharmaceuticals Inc. logo is available at http://www.primezone.com/newsroom/prs/?pkgid=2670
Disclaimer
The company disclaims any information that is created by an outside party and endorses only information that is communicated by its press releases, filings and Website. This news release contains forward-looking statements that reflect management's current beliefs about the potential for its drug candidates, science and technology. However, as with any biopharmaceutical under development, there are significant risks and uncertainties in the process of development and regulatory review. There are no guarantees that products will prove to be commercially successful. For additional information about the factors that affect the company's business, please read the company's latest Form 10-K filed April 13, 2006. The company undertakes no duty to update forward-looking statements.